Tripped up by the FDA, Novartis says it is dropping out of the US race to win an OK for a blockbuster Rituxan rival
Novartis may have had little trouble getting an EU approval for their knockoff of Roche’s Rituxan last year, but they’ve reached a dead end in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
